METAVIA INC (MTVA) Stock Price, Quote, News and Overview
NASDAQ:MTVA - Nasdaq - US64132R4048 - Common Stock - Currency: USD
MTVA Quote, Performance and Key Statistics
0.813
+0.06 (+8.4%)
The current stock price of MTVA is 0.813 USD. In the past month the price decreased by -48.68%.
MTVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About MTVA
Company Profile
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus resulting in body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, GLP-1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Company Info
METAVIA INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS US
Employees: 8
Company Website: https://metaviatx.com/
Investor Relations: http://www.neurobopharma.com/investor-overview
Phone: 18577029600
METAVIA INC / MTVA FAQ
What is the stock price of METAVIA INC today?
The current stock price of MTVA is 0.813 USD. The price increased by 8.4% in the last trading session.
What is the ticker symbol for METAVIA INC stock?
The exchange symbol of METAVIA INC is MTVA and it is listed on the Nasdaq exchange.
On which exchange is MTVA stock listed?
MTVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for METAVIA INC stock?
9 analysts have analysed MTVA and the average price target is 15.3 USD. This implies a price increase of 1781.92% is expected in the next year compared to the current price of 0.813. Check the METAVIA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is METAVIA INC worth?
METAVIA INC (MTVA) has a market capitalization of 8.20M USD. This makes MTVA a Nano Cap stock.
How many employees does METAVIA INC have?
METAVIA INC (MTVA) currently has 8 employees.
Should I buy METAVIA INC (MTVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MTVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MTVA, evaluating the profitability, health, valuation and growth aspects
- METAVIA INC (MTVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- METAVIA INC (MTVA) Sales and EPS estimates to see what analysts future expectations are.
- METAVIA INC (MTVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- METAVIA INC (MTVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- METAVIA INC (MTVA) Stock Chart to make your own analysis
- METAVIA INC (MTVA) Latest news and press-releases to stay up to date.
Does METAVIA INC (MTVA) stock pay dividends?
MTVA does not pay a dividend.
When does METAVIA INC (MTVA) report earnings?
METAVIA INC (MTVA) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of METAVIA INC (MTVA)?
METAVIA INC (MTVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.22).
What is the Short Interest ratio of METAVIA INC (MTVA) stock?
The outstanding short interest for METAVIA INC (MTVA) is 1.63% of its float. Check the ownership tab for more information on the MTVA short interest.
MTVA Technical Analysis
MTVA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MTVA. The financial health of MTVA is average, but there are quite some concerns on its profitability.
MTVA Financial Highlights
Over the last trailing twelve months MTVA reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS decreased by -7.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -169.69% | ||
| ROE | -347.9% | ||
| Debt/Equity | 0 |
MTVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to MTVA. The Buy consensus is the average rating of analysts ratings from 9 analysts.